The immunosuppressive effects of TGF-β enabling cancer progression and development of TGF-β inhibitors as antitumor agents have been discussed in the context of various cancers such as liver, cervical, breast, colon, lung, prostate, esophageal, and pancreatic cancer (23, 24). The gene discussed is TGFB1; the disease is pancreatic neoplasm.